|
KMID : 0358420120550110814
|
|
Korean Journal of Obstetrics and Gynecology
2012 Volume.55 No. 11 p.814 ~ p.821
|
|
|
Synergistic effects of sorafenib and celecoxib inhibit growth and VEGF expression in Hec-1A endometrial cancer cell line
|
|
Kim Jeong-Sig
Park Bo-Ra
Nam Kye-Hyun
Bae Dong-Han
|
|
|
Abstract
|
|
|
Objective: The aim of this study was to investigate whether combination of sorafenib and celecoxib exhibited an anti-tumor efficacy or altered expression of vascular endothelial growth factor (VEGF) in Hec-1A endometrial cancer cell line.
Methods: To determine whether sorafenib or celecoxib-induced growth inhibition was determined by the (3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium, inner salt) assay. Expression of VEGF and p53 were evaluated using the reverse transcription polymerase chain reaction.
Results: Combination of sorafenib 10 ng/mL and celecoxib 50 μmol/L exhibited synergistic inhibitory effects compared to treatment with each agent alone (P<0.0001). VEGF expression was also down regulated after 24 hours or 72 hours of treatment with sorafenib alone or in combination with sorafenib and celecoxib in Hec-1A cells. However, there was no alteration of p53 expression in Hec-1A cells after 24 hours or 72 hours of treatment with sorafenib alone or in combination with sorafenib and celecoxib.
Conclusion: Combination treatment of sorafenib and celecoxib to Hec-1A endometrial cancer cell line revealed the ability to inhibit growth and expression of VEGF.
|
|
|
KEYWORD
|
|
|
Endometrial cancer, Sorafenib, Celecoxib, Vascular endothelial growth factor
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
  
|